BiotechTube

XL820

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cancer

Conditions

Cancer

Trial Timeline

Aug 1, 2005 → —

NCT ID
NCT00129571

About XL820

XL820 is a phase 1 stage product being developed by Exelixis for Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00129571. Target conditions include Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Cancer were approved

Approved (20) Terminated (4) Active (0)
✅arzoxifeneEli LillyApproved
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + FlutamideAstellas PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00350831Phase 1Completed
NCT00129571Phase 1Completed

Competing Products

20 competing products in Cancer

See all competitors
ProductCompanyStageHype Score
mFOLFOX regimen + MitazalimabAlligator Bioscience ABPhase 2/3
35
Intratumoral Mitazalimab + Intratumoral NivolumabAlligator Bioscience ABPhase 1
26
mRNA-2416ModernaPhase 2
0
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
E7389EisaiPhase 1
29
VeliparibAbbViePhase 2
27
AK-105AkesoPhase 1
29
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
30
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
35
pemetrexedEli LillyPhase 2
27
LY3300054 + PrexasertibEli LillyPhase 1
29
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
35
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
35
SelpercatinibEli LillyPre-clinical
26